{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:42:51Z","timestamp":1782956571700,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.maturitas.2016.10.007","type":"journal-article","created":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T02:48:56Z","timestamp":1476067736000},"page":"65-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Osteoporosis management in patients with breast cancer: EMAS position statement"],"prefix":"10.1016","volume":"95","author":[{"given":"Florence A.","family":"Tr\u00e9mollieres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Ceausu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Depypere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lambrinoudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Mueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faustino R.","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne T.","family":"van der Schouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent M.","family":"Senturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Simoncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Stute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.maturitas.2016.10.007_bib0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.6004\/jnccn.2016.0181","article-title":"NCCN guidelines update: breast cancer","volume":"14","author":"Gradishar","year":"2016","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0010","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0020","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bone.2006.06.027","article-title":"Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane","volume":"40","author":"Gonnelli","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0030","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdn762","article-title":"Effects of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy","volume":"20","author":"Hadji","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0040","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1054\/bjoc.2001.1729","article-title":"The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer","volume":"84","author":"Saarto","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates","volume":"41","author":"Confavreux","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0050","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0055","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase III randomised, placebo-controlled double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer","volume":"27","author":"Hines","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0060","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0065","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr2565","article-title":"Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial","volume":"12","author":"Markopoulos","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0070","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S1470-2045(14)71035-6","article-title":"Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial","volume":"15","author":"Sestak","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0080","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0085","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study","volume":"21","author":"Eidtman","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0090","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0095","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","article-title":"Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial","volume":"12","author":"Llombart","year":"2012","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0105","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1002\/cncr.29327","article-title":"5-year follow-up of a randomised controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (alliance) trial","volume":"121","author":"Wagner-Johnston","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0110","first-page":"1219","article-title":"Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up","volume":"24","author":"Majithia","year":"2016","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0115","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian breast and colorectal cancer study group trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0125","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00198-013-2615-z","article-title":"Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study","volume":"25","author":"Hadji","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00198-014-2955-3","article-title":"Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy","volume":"26","author":"Kalder","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0135","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-011-1728-3","article-title":"Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients","volume":"130","author":"Lee","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0140","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdu008","article-title":"Fracture incidence after 3 years of aromatase inhibitor therapy","volume":"25","author":"Bouvard","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0145","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors: results from the women\u2019s health initiative observational study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0150","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1200\/JCO.2007.15.7123","article-title":"Tamoxifen use and osteoporotic fracture risk: a population-based analysis","volume":"26","author":"Cooke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0155","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/02841860802167490","article-title":"Fracture risk in patients with different types of cancer","volume":"48","author":"Vestergaard","year":"2009","journal-title":"Acta Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0160","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non metastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0170","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0175","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"133","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0180","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ctrv.2011.09.003","article-title":"Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature","volume":"38","author":"Gnant","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0185","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0190","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0195","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0200","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0205","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0210","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0215","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.maturitas.2014.08.001","article-title":"Screening for osteoporosis after breast cancer: for whom, why and when","volume":"79","author":"Tremollieres","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2016.10.007_bib0220","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdr356","article-title":"High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy","volume":"23","author":"Bouvard","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0225","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0230","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0235","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","article-title":"Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment","volume":"22","author":"Hadji","year":"2011","journal-title":"Ann. Oncol."},{"issue":"S1","key":"10.1016\/j.maturitas.2016.10.007_bib0240","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0245","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00198-011-1870-0","article-title":"Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper","volume":"23","author":"Rizzoli","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"S3","key":"10.1016\/j.maturitas.2016.10.007_bib0250","first-page":"125","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0255","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0260","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","article-title":"Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk\u2014a perspective","volume":"27","author":"Boonen","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2016.10.007_bib0265","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur. J. Cancer"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512216302572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512216302572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:07:24Z","timestamp":1759914444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512216302572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":53,"alternative-id":["S0378512216302572"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2016.10.007","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoporosis management in patients with breast cancer: EMAS position statement","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2016.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}